QUINIDINE SULFATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for quinidine sulfate and what is the scope of patent protection?
Quinidine sulfate
is the generic ingredient in four branded drugs marketed by Solvay, Lilly, Wyeth Pharms Inc, Cosette, Barr, Chartwell Molecular, Chartwell Rx, Contract Pharmacal, Cycle, Dava Pharms Inc, Elkins Sinn, Epic Pharma Llc, Everylife, Halsey, Hikma, Impax Labs, Ivax Sub Teva Pharms, King Pharms, Kv Pharm, Lederle, Perrigo, Pharmavite, Purepac Pharm, Sandoz, Scherer Labs, Sun Pharm Industries, Superpharm, Usl Pharma, Valeant Pharm Intl, Vangard, Vintage Pharms, Warner Chilcott, Watson Labs, Whiteworth Town Plsn, Key Pharms, and Schering, and is included in forty-eight NDAs. Additional information is available in the individual branded drug profile pages.There are eight drug master file entries for quinidine sulfate. Two suppliers are listed for this compound.
Summary for QUINIDINE SULFATE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 36 |
| NDAs: | 48 |
| Drug Master File Entries: | 8 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 214 |
| Clinical Trials: | 21 |
| Patent Applications: | 4,971 |
| Drug Prices: | Drug price trends for QUINIDINE SULFATE |
| What excipients (inactive ingredients) are in QUINIDINE SULFATE? | QUINIDINE SULFATE excipients list |
| DailyMed Link: | QUINIDINE SULFATE at DailyMed |
Recent Clinical Trials for QUINIDINE SULFATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| ALS Association | Phase 1/Phase 2 |
| University of Florida | Phase 1/Phase 2 |
| Holy Cross Hospital, Florida | Phase 1/Phase 2 |
Pharmacology for QUINIDINE SULFATE
| Drug Class | Antiarrhythmic Cytochrome P450 2D6 Inhibitor |
| Mechanism of Action | Cytochrome P450 2D6 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for QUINIDINE SULFATE
US Patents and Regulatory Information for QUINIDINE SULFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 089839-001 | Sep 29, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 085583-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Usl Pharma | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 087837-001 | Apr 14, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Whiteworth Town Plsn | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 085444-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pharmavite | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 084627-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Perrigo | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 085322-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 085038-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
